CIA
LGND icon

Cape Investment Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

Cape Investment Advisory’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06K Buy
+16
New +$3.77K ﹤0.01% 1026
2026
Q1 		– Sell
-8
Closed -$1.51K – 758
2025
Q4 		$1.51K Buy
+8
New +$1.54K ﹤0.01% 1144
2025
Q2 		– Sell
-63
Closed -$6.62K – 1216
2025
Q1 		$6.62K Hold
63
– – ﹤0.01% 682
2024
Q4 		$6.75K Hold
63
– – ﹤0.01% 670
2024
Q3 		$6.31K Hold
63
– – ﹤0.01% 657
2024
Q2 		$5.31K Buy
+63
New +$5.01K ﹤0.01% 650

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cape Investment Advisory's LGND Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 16 shares worth $5.06K. The stake represents ﹤0.01% of the portfolio and ranks #1026 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in LGND as recently as Q4 2025.

Cape Investment Advisory first reported a position in LGND in Q2 2024 and has held it in 6 quarters since. The position peaked at $6.75K in Q4 2024. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Cape Investment Advisory held 16 shares of Ligand Pharmaceuticals worth $5.06K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1026 holding.
  • Cape Investment Advisory first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Cape Investment Advisory's Ligand Pharmaceuticals position peaked at $6.75K in Q4 2024.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.